Advertisement
UK markets close in 34 minutes

  • FTSE 100

    8,040.00
    +16.13 (+0.20%)
     

  • FTSE 250

    19,759.44
    +160.05 (+0.82%)
     

  • AIM

    755.01
    +5.83 (+0.78%)
     

  • GBP/EUR

    1.1623
    +0.0034 (+0.30%)
     

  • GBP/USD

    1.2435
    +0.0085 (+0.69%)
     

  • Bitcoin GBP

    53,834.46
    +503.74 (+0.94%)
     

  • CMC Crypto 200

    1,441.34
    +26.58 (+1.88%)
     

  • S&P 500

    5,065.07
    +54.47 (+1.09%)
     

  • DOW

    38,482.38
    +242.40 (+0.63%)
     

  • CRUDE OIL

    82.14
    +0.24 (+0.29%)
     

  • GOLD FUTURES

    2,331.00
    -15.40 (-0.66%)
     

  • NIKKEI 225

    37,552.16
    +113.55 (+0.30%)
     

  • HANG SENG

    16,828.93
    +317.24 (+1.92%)
     

  • DAX

    18,101.64
    +240.84 (+1.35%)
     

  • CAC 40

    8,097.18
    +56.82 (+0.71%)
     
Money:

What is the true cost of the UK state pension?

To get a sense of the true value of the state pension, you can look at how much you would need to save to match it yourself

J&J's Tuberculosis Drug Gets FDA Nod for Adolescent Patients

Zacks Equity Research

Johnson & Johnson JNJ announced that the FDA has granted accelerated approval to its antimycobacterial tablets, Sirturo (bedaquiline) as a combination therapy to treat adolescents with pulmonary multidrug-resistant tuberculosis (MDR-TB).

Sirturo is already marketed in combination with a background regimen for treating MDR-TB in adults. Continued approval for the adolescent indication will be based on verification of data from confirmatory studies. A similar application is also under review in the EU.

The approval for Sirturo in adolescents patient group (12 to less than 18 years of age and weighing at least 30 kg) was based on a cohort of a J&J phase II pediatric pharmacokinetic and safety study, C211. The other cohorts of the study are evaluating Sirturo in pediatric patients in different age groups. For the adolescent patient group, the formulation (100 mg tablet) and the dosing recommendation are the same as those approved for adults.

Tuberculosis is a deadly infectious disease, which claimed the lives of 230,000 children in 2017. Though it is more common in adult patients, all age groups are at risk.

ADVERTISEMENT

J&J’s stock has risen 2.3% this year so far against a decrease of 1.3% recorded by the industry.

 

 

J&J currently has a Zacks Rank #3 (Hold). Some better-ranked large-cap pharma stocks are Roche Holding AG RHHBY, Sanofi SNY and Merck MRK. While Roche sports a Zacks Rank #1 (Strong Buy), Sanofi and Merck carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Shares of Roche have gained 12.3% this year so far. Earnings estimates for 2019 have risen 0.8% while that for 2020 have increased 2% over the past 30 days.

Sanofi’s earnings estimates have increased 0.3% and 0.9%, respectively, for 2019 and 2020 over the past 30 days.

Merck’s stock is up 11.9% this year so far. Its earnings estimates have risen almost 3% for 2019 and 1.7% for 2020 over the past 30 days.

Today's Best Stocks from Zacks

Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.

This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.

See their latest picks free >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Roche Holding AG (RHHBY) : Free Stock Analysis Report
 
Sanofi (SNY) : Free Stock Analysis Report
 
Johnson & Johnson (JNJ) : Free Stock Analysis Report
 
Merck & Co., Inc. (MRK) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.